626 related articles for article (PubMed ID: 11874940)
21. The effect of pioglitazone on the liver: role of adiponectin.
Gastaldelli A; Miyazaki Y; Mahankali A; Berria R; Pettiti M; Buzzigoli E; Ferrannini E; DeFronzo RA
Diabetes Care; 2006 Oct; 29(10):2275-81. PubMed ID: 17003306
[TBL] [Abstract][Full Text] [Related]
22. Insulin secretion and insulin sensitivity on the oral glucose tolerance test (OGTT) in middle-aged Japanese.
Oka R; Yagi K; Sakurai M; Nakamura K; Moriuchi T; Miyamoto S; Nohara A; Kawashiri MA; Takeda Y; Yamagishi M
Endocr J; 2012; 59(1):55-64. PubMed ID: 22068110
[TBL] [Abstract][Full Text] [Related]
23. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
24. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
25. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
Mori Y; Itoh Y; Obata T; Tajima N
Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
[TBL] [Abstract][Full Text] [Related]
26. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
[TBL] [Abstract][Full Text] [Related]
27. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
28. Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.
Iwamoto Y; Kuzuya T; Matsuda A; Awata T; Kumakura S; Inooka G; Shiraishi I
Diabetes Care; 1991 Nov; 14(11):1083-6. PubMed ID: 1797492
[TBL] [Abstract][Full Text] [Related]
29. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
[TBL] [Abstract][Full Text] [Related]
30. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose.
Abdul-Ghani MA; Williams K; DeFronzo R; Stern M
Diabetes Care; 2006 Jul; 29(7):1613-8. PubMed ID: 16801587
[TBL] [Abstract][Full Text] [Related]
31. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
Kautzky-Willer A; Tura A; Winzer C; Wagner OF; Ludvik B; Hanusch-Enserer U; Prager R; Pacini G
Diabetes Obes Metab; 2006 Sep; 8(5):561-7. PubMed ID: 16918591
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
33. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
[TBL] [Abstract][Full Text] [Related]
35. Decreased beta cell function and insulin sensitivity contributed to increasing fasting glucose in Chinese.
Bi Y; Zhu D; Jing Y; Hu Y; Feng W; Shen S; Tong G; Shen X; Yu T; Song D; Yang D
Acta Diabetol; 2012 Dec; 49 Suppl 1():S51-8. PubMed ID: 20473530
[TBL] [Abstract][Full Text] [Related]
36. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
37. Bromocriptine: a novel approach to the treatment of type 2 diabetes.
Pijl H; Ohashi S; Matsuda M; Miyazaki Y; Mahankali A; Kumar V; Pipek R; Iozzo P; Lancaster JL; Cincotta AH; DeFronzo RA
Diabetes Care; 2000 Aug; 23(8):1154-61. PubMed ID: 10937514
[TBL] [Abstract][Full Text] [Related]
38. Use of glimepiride and insulin sensitizers in the treatment of type 2 diabetes--a study in Indians.
Ramachandran A; Snehalatha C; Salini J; Vijay V
J Assoc Physicians India; 2004 Jun; 52():459-63. PubMed ID: 15645955
[TBL] [Abstract][Full Text] [Related]
39. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion.
Lee WJ; Ser KH; Chong K; Lee YC; Chen SC; Tsou JJ; Chen JC; Chen CM
Surgery; 2010 May; 147(5):664-9. PubMed ID: 20004451
[TBL] [Abstract][Full Text] [Related]
40. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus.
Kudolo GB
J Clin Pharmacol; 2001 Jun; 41(6):600-11. PubMed ID: 11402628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
